Doses will be ready to ship to applicable European Union (EU) member states as soon as possible upon European Commission (EC) authorization
New indication supported by the MANDARA trial which showed nearly 60% of patients achieved remission and 41% of patients fully stopped taking oral corticosteroids
The updated COVID-19 vaccine is tailored to the KP.2 strain of the SARS-CoV-2 Omicron JN.1 lineage and is recommended for individuals 6 months of age and older
CN201 is a next generation CD3xCD19 bispecific antibody that augments and diversifies Merck’s pipeline, with potential applications in B-cell malignancies and autoimmune diseases
The partnership will focus on creating capabilities for quickly and accurately processing vast amounts of clinical data
Doses will be ready to ship to applicable EU member states immediately upon authorization by the European Commission
Private financing round supported by Fidelity Management & Research Company, T. Rowe Price and Durable Capital Partners
Late-breaker Phase 3 STRIDE-10 trial presented as an oral presentation at European Society of Clinical Microbiology and Infectious Diseases
Strategic multi-year research collaboration to identify novel targets with strong disease links and to accelerate clinical development
Launches collaborative centre for translational research in head and neck cancer
Subscribe To Our Newsletter & Stay Updated
